Abstract: There is disclosed a peptide capable of inducing an immune response against: a ASTE1-1a frameshift mutant protein, wherein the peptide comprises at least 10 consecutive amino acids of SEQ ID NO: 26; a TAE1?-1a frameshift mutant protein, wherein the peptide comprises at least 10 consecutive amino acids of SEQ ID NO: 27; a KIAA2018-1a frameshift mutant protein, wherein the peptide comprises a immunogenic fragment of one of SEQ ID NOs: 9-12, wherein the fragment comprises at least 8 consecutive amino acids of one of one of SEQ ID NOs: 9-12; or a SLC22A9-1a frameshift mutant protein, wherein the peptide comprises at least 8 consecutive amino acids of one of SEQ ID NOs: 14-18. There is also disclosed a peptide mixture comprising a first and second peptide, each independently selected from one of the peptides described above and a peptide capable of inducing an immune response against a T?E?E2-1a frameshift mutant protein.

Abstract: The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations containing them.

Abstract: The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 1-?-D-arabinofuranosylcytosine (cytarabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.

Abstract: The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 1-?-D-arabinofuranosylcytosine (cytarabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.

Abstract: The present invention is directed toward compounds of Formula (I) as follows: wherein, R is H, R5C(O), R5CH2OC(O), or R5CH2NHC(O); R1 is where the crossing dashed line illustrates the bond formed joining R1 to the molecule of Formula (I); R2 and R3 are independently OH or H, provided that R2 and R3 are not simultaneously OH; R4 is H, R5C(O), R5CH2OC(O), or R5CH2NHC(O), provided that R and R4 are not simultaneously H; and R5 has the general formula: CH3—(CH2)n—(CH?CH—CH2)m—CH?CH—(CH2)k—; k is an integer from 0 to 7; m is an integer from 0 to 2; and n is an integer from 0 to 10, or a pharmaceutical salt thereof. Methods of making and using these compounds are also disclosed.

Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives fall within formula (I). Compounds of formula (I) can be used in the treatment of a cancerous disease, including solid tumors and haematological cancers such as leukaemias, lymphomas and multiple myelomas.

Abstract: The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 2?,2?-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.

Abstract: The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations containing them.

Abstract: A method for producing a feedstuff or feedstuff component, e.g., a palatability-enhancing agent, said method comprising subjecting a microbial culture which comprises a methanotrophic bacterium to autolysis.

Abstract: A method for producing a feedstuff or feedstuff component, e.g. a palatability-enhancing agent, said method comprising subjecting a microbial culture which comprises a methanotrophic bacterium to enzymatic hydrolysis.

Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula (I)” herein. Compounds of formula (I) can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.

Abstract: The invention provides a process for the production of biomass by culturing a microorganism in an aqueous liquid culture medium circulating in a loop reactor having an effluent gas removal zone where from carbon dioxide-containing effluent gas is removed from the reactor and upstream thereof a degassing zone in which a driving gas is introduced to drive carbon dioxide in the liquid phase into a separable effluent gas phase and having upstream of said degassing zone a nutrient gas introduction zone in which oxygen is introduced into the reactor and mixed with the liquid culture medium therein, characterized in that oxygen introduction in said nutrient gas introduction zone is effected at a plurality of locations along the flow path through said loop reactor at a rate such that the average dissolved oxygen content of said liquid culture medium measured using a polarographic oxygen electrode does not exceed 25 ppm.

Abstract: The invention provides a process for the production of biomass by culturing a microorganism in an aqueous liquid culture medium circulating in a loop reactor having an effluent gas removal zone where from carbon dioxide-containing effluent gas is removed from the reactor and upstream thereof a degassing zone in which a driving gas is introduced to drive carbon dioxide in the liquid phase into a separable effluent gas phase and having upstream of said degassing zone a nutrient gas introduction zone in which oxygen is introduced into the reactor and mixed with the liquid culture medium therein, characterised in that oxygen introduction in said nutrient gas introduction zone is effected at a plurality of locations along the flow path through said loop reactor at a rate such that the average dissolved oxygen content of said liquid culture medium measured using a polarographic oxygen electrode does not exceed 25 ppm.

Abstract: The present invention is directed toward compounds of Formula (I) as follows: wherein, R is H, R5C(O), R5CH2OC(O), or R5CH2NHC(O); R1 is where the crossing dashed line illustrates the bond formed joining R1 to the molecule of Formula (I); R2 and R3 are independently OH or H, provided that R2 and R3 are not simultaneously OH; R4 is H, R5C(O), R5CH2OC(O), or R5CH2NHC(O), provided that R and R4 are not simultaneously H; and R5 has the general formula: CH3—(CH2)n—(CH?CH—CH2)m—CH?CH—(CH2)k—; k is an integer from 0 to 7; m is an integer from 0 to 2; and n is an integer from 0 to 10, or a pharmaceutical salt thereof. Methods of making and using these compounds are also disclosed.

Abstract: A method for producing a feedstuff or feedstuff component, e.g., a palatability-enhancing agent, said method comprising subjecting a microbial culture which comprises a methanotrophic bacterium to autolysis.

Abstract: A method for producing a feedstuff or feedstuff component, e.g. a palatability-enhancing agent, said method comprising subjecting a microbial culture which comprises a methanotrophic bacterium to enzymatic hydrolysis.

Abstract: The invention provides a process for the production of biomass by culturing a microorganism in an aqueous liquid culture medium circulating in a loop reactor having an effluent gas removal zone where from carbon dioxide-containing effluent gas is removed from the reactor and upstream thereof a degassing zone in which a driving gas is introduced to drive carbon dioxide in the liquid phase into a separable effluent gas phase and having upstream of said degassing zone a nutrient gas introduction zone in which oxygen is introduced into the reactor and mixed with the liquid culture medium therein, characterised in that oxygen introduction in said nutrient gas introduction zone is effected at a plurality of locations along the flow path through said loop reactor at a rate such that the average dissolved oxygen content of said liquid culture medium measured using a polarographic oxygen electrode does not exceed 25 ppm.

Abstract: An apparatus for assisting percutaneous light beam guided biopsy, having means for rotating a laser device about first and second rotation axes, the laser device providing its laser beam along an axis intersecting an intersection point between the first and second rotation axes and at right angles thereto. Inclinometers are installed for providing signal values as a function of two- or three-dimensional orientation directions of the said laser device relative to direction of gravitation. Encoding means provide feedback of rotary position information of the laser device. Comparing means compare set calculated instrument insertion angle values, provided from an input device, with encoder feedback signals and inclinometer signals and inhibits rotation operation of the laser device upon reaching specific threshold values.

Abstract: An apparatus for assisting percutaneous light beam guided biopsy, having means for rotating a laser device about first and second rotation axis, said laser device providing its laser beam along an axis intersecting an intersection point between said first and second rotation axis and at right angles thereto.